Vivus, Inc.: VVUS (NASDAQ)
Vivus has increased in value by over 60% since 12/31/2001.
VIVUS (VVUS) Earnings Conference Call (Q4 2001)
Scheduled to start Wed, Jan 23, 2002, 4:30 pm Eastern
1/18/02 Vivus Inc. (VVUS) rose $1.20, or 17 percent, to $8.20 and traded as high as $8.35. CE Unterberg, Towbin analyst Ken Trbovich expects the company, whose Muse product is used to treat erectile dysfunction, to reach $14 within 12 months, up from his previous estimate of $7. He maintains his ``strong buy'' rating.
VIVUS goal is to establish a robust pipeline consisting of drug candidates at various stages of development, with a focus on innovative therapies intended to serve large and unsatisfied markets. In addition to the Companys currently marketed products, MUSE. and ACTIS., VIVUS is developing products for male erectile dysfunction, female sexual dysfunction, and premature ejaculation.
GO to WWW.VIVUS.COM for complete product pipeline information.
CONTACT: VIVUS Inc.
Richard Walliser, 650/934-5200
ir@vivus.com
www.vivus.com
or
Lippert/Heilshorn & Associates Inc.
Bruce Voss, 310/691-7100 (Investor Contacts)
bvoss@lhai.com
Jody Cain, 310/691-7100 (Investor Contacts)
jcain@lhai.com
Elissa Grabowski, 212/838-3777 (Media Contact)
egrabowski@lhai.com
www.lhai.com |
